VIDEOS

Who can benefit from ICS

02:02

Who can benefit from ICS
Superiority of LABA/LAMA over LABA/ICS

02:02

Superiority of LABA/LAMA over LABA/ICS
Respimat for First Use - Teacher

01:15

Respimat for First Use - Teacher
OTIVACTO animation storyboard

02:37

OTIVACTO animation storyboard
Actilyse Infusion Preparation

03:16

Actilyse Infusion Preparation
Treatment Including Thrombolysis

01:19

Treatment Including Thrombolysis
Stroke Causes and Diagnosis

02:22

Stroke Causes and Diagnosis
Recognition of Stroke

02:09

Recognition of Stroke
Metalyse Administration Video

02:13

Metalyse Administration Video
What is the leading cause of death in patients with type 2 diabetes?

01:32

What is the leading cause of death in patients with type 2 diabetes?
EMPA-REG Outcome Results - Video

02:30

EMPA-REG Outcome Results - Video
What are your thoughts on the 35% relative risk reduction?

01:42

What are your thoughts on the 35% relative risk reduction?
Efficacy with Concomitant Emphysema

03:17

Efficacy with Concomitant Emphysema
Idarucizumab (Praxbind®) patient case in gallbladder removal

01:29

Idarucizumab (Praxbind®) patient case in gallbladder removal
RE-VERSE AD Study: Dr. Charles Pollack

03:11

RE-VERSE AD Study: Dr. Charles Pollack
Idarucizumab (Praxbind®) real patient cases

03:00

Idarucizumab (Praxbind®) real patient cases
Reversibility of NOAC therapies: the neurologist's perspective

06:12

Reversibility of NOAC therapies: the neurologist's perspective
Dosage & Administration

01:18

Dosage & Administration
Praxbind from a neurologist perspective

06:19

Praxbind from a neurologist perspective
Real-life patient

02:35

Real-Life Patient
Dr Tim Woods overview on reversibility

04:19

Dr. Tim Woods Overview On Reversibility
RE-DUAL vs pioneer infographic_dose comparison

icoPDF

RE-DUAL Vs Pioneer Infographic Dose Comparison
RE-DUAL vs pioneer infographic_primary outcome measure comparison

icoPDF

RE-DUAL Vs Pioneer Infographic Primary Outcome Measure Comparison
Patient Gallbladder removal story

01:32

Patient Gallbladder Removal Story
Patient Fall in Shower story

01:30

Patient Fall In Shower story
Praxbind How to Use

01:33

Praxbind How to Use
Life Happens - Bike Accident

01:01

Life Happens - Bike Accident
LIFE CASE PRAXBIND

02:58

LIFE CASE PRAXBIND
Life Happens - Emergency Surgery

00:52

Life Happens - Emergency Surgery
Dr. Todd Villines overview on Pradaxa’s Safety

09:06

Dr. Todd Villines overview on Pradaxa’s Safety
Dr. Kenigsberg overview on efficacy, safety & reversibility

06:33

Dr. Kenigsberg overview on efficacy, safety & reversibility
Pradaxa Global Car Crash

00:53

Pradaxa Global Car Crash
Changing clinical practice - The Re-Circuit Study by Dr Dhiraj Gupta video

03:33

Changing clinical practice - The Re-Circuit Study by Dr Dhiraj Gupta video
Pradaxa Side by Side Video

02:17

Pradaxa Side by Side Video
RE-DUAL PCI smart video (with subanalyses)

03:14

RE-DUAL PCI smart video (with subanalyses)
Prof. Hugh Calkins Video

07:09

Prof. Hugh Calkins Video
Pradaxa GLORIA-AF infographic animation (abbreviated version without RE-LY EU label analysis)

02:56

Pradaxa GLORIA-AF Infographic Animation (Abbreviated Version Without RE-LY EU Label Analysis)
Pradaxa Story in Reverse Video

01:18

Pradaxa Story in Reverse Video
Mechanism of Action

03:20

Mechanism of Action
INPULSIS-ON Prof. Richeldi & Prof. Maher video: Early use of antifibrotics and the benefit to patients ?

00:58

INPULSIS-ON Prof. Richeldi & Prof. Maher video: Early use of antifibrotics and the benefit to patients ?
Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?

01:50

Prof. Richeldi & Prof. Maher video transcript: Why watch & wait?
Prof. Richeldi & Prof. Maher Interpreting acute exacerbations data from INPULSIS-ON trial

02:06

Prof. Richeldi & Prof. Maher Interpreting acute exacerbations data from INPULSIS-ON trial
Is it safe to use OFEV for more than 4 years?

06:53

Is it safe to use OFEV for more than 4 years?
Reducing Acute Exacerbation

01:06

Reducing Acute Exacerbation
Prof. Richeldi & Prof. Maher video: evaluating FVC data from INPULSIS-ON trial

02:013

Prof. Richeldi & Prof. Maher video: evaluating FVC data from INPULSIS-ON trial
OFEV - INPULSIS ON: Mortality data (Dr Maher- Dr Richaldi)

02:22

OFEV - INPULSIS ON: Mortality data (Dr Maher- Dr Richaldi)
OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)

02:16

OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)
INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline impact on the diagnosis of IPF

01:06

INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline impact on the diagnosis of IPF
Expert Opinion

00:57

Expert Opinion
Survival Analysis

05:58

Survival Analysis
About IPF - Intro

00:51

About IPF - Intro
Dose Modification

02:47

Dose Modification
About IPF - Tissue Repair

01:41

About IPF - Tissue Repair
Patients Subgroup Analysis

09:33

Patients Subgroup Analysis
Lung Function at Baseline

03:02

Lung Function at Baseline
Why was the data of the INPULSIS<sup>®</sup> and TOMORROW trials pooled?

02:03

Why was the data of the INPULSIS® and TOMORROW trials pooled?
Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?

01:52

Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?
What were the key findings from EMPA-REG OUTCOME?

02:29

What were the key findings from EMPA-REG OUTCOME?
Should we move beyond glucose lowering as the main treatment goal?

02:46

Should we move beyond glucose lowering as the main treatment goal?
What does lowering the risk of CV death? - John Wilding

01:56

What does lowering the risk of CV death? - John Wilding
Are patients with type 2 diabetes at elevated CV risk?

02:23

Are patients with type 2 diabetes at elevated CV risk?
Safety & Tolerability

03:20

Safety & Tolerability
Early reduction in CV death with Jardiance

01:01

Early reduction in CV death with Jardiance
Reduce the risk of mortality with Jardiance

01:01

Reduce the risk of mortality with Jardiance
Reduce the risk of hospitalization for heart failure with Jardiance

01:01

Reduce the risk of hospitalization for heart failure with Jardiance
EMPA-REG Outcome Results - Video

02:30

EMPA-REG Outcome Results - Video
Patients could benefit from Jardiance across baseline HbA1c

01:00

Patients could benefit from Jardiance across baseline HbA1c
Going beyond standard care of with Jardiance

01:03

Going beyond standard care of with Jardiance
Reduce the risk of CV death with Jardiance-38 Percent

01:01

Reduce the risk of CV death with Jardiance - 38%
Is Jardiance a medication for both endocrinologists and cardiologists?

02:23

Is Jardiance a medication for both endocrinologists and cardiologists?
What are your views on the 38% relative risk reduction in CV death with Jardiance?

02:22

What are your views on the 38% relative risk reduction in CV death with Jardiance?
What does lowering the risk of CV death? - Lars Ryden

01:51

What does lowering the risk of CV death? - Lars Ryden
What are your thoughts on the 35% relative risk reduction?

01:42

What are your thoughts on the 35% relative risk reduction?
Reduce the risk of CV death with Jardiance - 1/3

01:01

Reduce the risk of CV death with Jardiance - 1/3
Long term benefit of Jardiance on life expectancy

01:00

Long term benefit of Jardiance on life expectancy
Effect On Honeycombing Efficacy

02:44

Effect On Honeycombing Efficacy
Simplification of T2D therapy with Linagliptin (Trajenta®): 5mg once daily, the same dose regardless of renal function

0:37

Simplification of T2D therapy with Linagliptin (Trajenta®): 5mg once daily, the same dose regardless of renal function
Linagliptin (Trajenta®): no extra monitoring of renal function for the sake of dose adjustment

0:34

Linagliptin (Trajenta®): no extra monitoring of renal function for the sake of dose adjustment
Linagliptin (Trajenta®) has the benefits of the DPP4i class plus no dose reduction regardless of renal function

0:41

Linagliptin (Trajenta®) has the benefits of the DPP4i class plus no dose reduction regardless of renal function
Complexity of T2D treatment accounts for not appropriately adjusting doses

0:39

Complexity of T2D treatment accounts for not appropriately adjusting doses
CVOTs CARMELINA: What is the impact of the unique eGFR cut-off (>15) and high risk renal patients inclusion in the CARMELINA study?

0:44

CVOTs CARMELINA: What is the impact of the unique eGFR cut-off (>15) and high risk renal patients inclusion in the CARMELINA study?
CVOTs CARMELINA: Prof. Ted Wu, the value of CARMELINA FOR T2D

0:47

CVOTs CARMELINA: Prof. Ted Wu, the value of CARMELINA FOR T2D
Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function

01:00

CVOTs CARMELINA: What is the impact of the eGFR cut-off of >15 in the CARMELINA trial?
CVOTs CARMELINA: Prof. M. Cooper on Clinical implication of CARMELINA

00:46

CVOTs CARMELINA: Prof. M. Cooper on Clinical implication of CARMELINA
Linagliptin (Trajenta®): comparable efficacy within DPP4i and a simple way to keep patients on a licensed dose

0:42

Linagliptin (Trajenta®): comparable efficacy within DPP4i and a simple way to keep patients on a licensed dose
Linagliptin (Trajenta®): proven HbA1c reduction with the same dose at any stage of renal function

0:29

Linagliptin (Trajenta®): proven HbA1c reduction with the same dose at any stage of renal function
Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function

0:44

Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function
Linagliptin (Trajenta®) has demonstrated high efficacy on a broad range of T2D populations regardless of renal function

1:06

Linagliptin (Trajenta®) has demonstrated high efficacy on a broad range of T2D populations regardless of renal function
Linagliptin (Trajenta®) can be used even before renal function declines

0:55

Linagliptin (Trajenta®) can be used even before renal function declines
DPP4i are similar in terms of HbA1c lowering

0:18

DPP4i are similar in terms of HbA1c lowering
Higher efficacy in HbA1c patients

0:45

Higher efficacy in HbA1c patients
Load more